Mushroom-derived compound lengthens survival in dogs with cancer

Sep 10, 2012

Dogs with hemangiosarcoma that were treated with a compound derived from the Coriolus versicolor mushroom had the longest survival times ever reported for dogs with the disease. These promising findings offer hope that the compound may one day offer cancer patients—human and canine alike—a viable alternative or complementary treatment to traditional chemotherapies.

The study was conducted by two University of Pennsylvania School of Veterinary Medicine faculty. Dorothy Cimino Brown is professor and chair of the Department of Clinical Studies and director of the Veterinary Clinical Investigation Center. Jennifer Reetz is an attending radiologist in the Department of Clinical Studies. They published their findings in an open-access article in the journal Evidence-Based .

The Coriolus versicolor mushroom, known commonly as the Yunzhi mushroom, has been used in for more than 2,000 years. The compound in the mushroom that is believed to have immune-boosting properties is polysaccharopeptide, or PSP. In the last two decades, some studies have suggested that PSP also has a tumor-fighting effect.

"There have been a series of studies looking at groups of people with cancer," Cimino Brown said. "The issue with those studies is that they weren't necessarily measuring what most people would think is the most clinically important result, which is, do people taking PSP live longer?"

To address this critical question, Cimino Brown and Reetz pursued a study in with naturally occurring hemangiosarcoma, an aggressive, that arises from the and typically affects the spleen. It commonly strikes golden retrievers and German shepherds.

Fifteen dogs that had been diagnosed with hemangiosarcoma participated in the trial. Divided into three groups of five, each group received a different dose—25, 50 or 100 mg/kg/day—of I'm-Yunity, a formulation of PSP that has been tested for consistency and good manufacturing processes.

The owners were instructed to give their dog capsules of I'm-Yunity, compounded by Penn pharmacists, daily. Each month, the owners brought their dogs to Penn's Ryan Veterinary Hospital for follow-up visits. There, the researchers took blood samples and conducted ultrasounds to determine the extent that tumors developed or grew and spread in the dogs' bodies.

Based on the ultimate endpoints—how quickly the tumors progressed and how long the dogs actually lived—the results of the researchers' trial suggest that the I'm-Yunity was effectively fighting the tumors.

"We were shocked," Cimino Brown said. "Prior to this, the longest reported median survival time of dogs with hemangiosarcoma of the spleen that underwent no further treatment was 86 days. We had dogs that lived beyond a year with nothing other than this mushroom as treatment."

There were not statistically significant differences in survival between the three dosage groups, though the median survival time was highest in the 100 mg group, at 199 days, eclipsing the previously reported median survival time.

The results were so surprising, in fact, that the researchers asked Penn Vet pathologists to recheck the dogs' tissue biopsies to make sure that the dogs really had the disease.

"They reread the samples and said, yes, it's really hemangiosarcoma," Cimino Brown said.

is available for treating hemangiosarcoma, but many owners opt not to pursue that treatment once their dog is diagnosed.

"It doesn't hugely increase survival, it's expensive and it means a lot of back and forth to the vet for the dog," Cimino Brown said. "So you have to figure in quality of life."

While I'm-Yunity is not inexpensive, if proven effective, it would offer owners a way of extending their pet's life without regular trips to the vet. As an added benefit, Cimino Brown and Reetz have found no evidence of adverse effects from the PSP treatment.

The researchers are now getting ready to pursue further trials of I'm-Yunity in dogs with hemangiosarcoma to confirm and refine their results. One trial will compare I'm-Yunity to a placebo for those owners who opt not to pursue chemotherapy in their pet and another will compare the compound to standard-of-care chemotherapy.

Depending on those results, veterinarians could eventually prescribe the compound for treating hemangiosarcoma, and perhaps other cancers, in dogs. The company that manufacturers I'm-Yunity may also pursue large-scale clinical trials in humans.

"Although hemangiosarcoma is a very sad and devastating disease," Cimino Brown said, "in the long term, if we prove that this works, this treatment can be a really nice alternative for owners to have increased quality time with their pet at the end of its life."

Explore further: Male monkey filmed caring for dying mate (w/ Video)

add to favorites email to friend print save as pdf

Related Stories

Penn State studies storm-phobic canines

Dec 15, 2005

Penn State University researchers have determined pet owners can't resolve storm phobia in their dogs, but having a multi-dog home may reduce stress.

Recommended for you

Male monkey filmed caring for dying mate (w/ Video)

Apr 18, 2014

(Phys.org) —The incident was captured by Dr Bruna Bezerra and colleagues in the Atlantic Forest in the Northeast of Brazil.  Dr Bezerra is a Research Associate at the University of Bristol and a Professor ...

Orchid named after UC Riverside researcher

Apr 17, 2014

One day about eight years ago, Katia Silvera, a postdoctoral scholar at the University of California, Riverside, and her father were on a field trip in a mountainous area in central Panama when they stumbled ...

In sex-reversed cave insects, females have the penises

Apr 17, 2014

Researchers reporting in the Cell Press journal Current Biology on April 17 have discovered little-known cave insects with rather novel sex lives. The Brazilian insects, which represent four distinct but re ...

Fear of the cuckoo mafia

Apr 17, 2014

If a restaurant owner fails to pay the protection money demanded of him, he can expect his premises to be trashed. Warnings like these are seldom required, however, as fear of the consequences is enough to ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Birger
not rated yet Sep 10, 2012
The current drug for hemangiosarcoma has awful side effects (it is called "the red devil"), which is why I chose to put my much-beloved tomcat down when he got the disease instead of trying medication.
I hope polysaccharopeptide, or PSP, will be cleared for use soon.

More news stories

Plants with dormant seeds give rise to more species

Seeds that sprout as soon as they're planted may be good news for a garden. But wild plants need to be more careful. In the wild, a plant whose seeds sprouted at the first warm spell or rainy day would risk disaster. More ...

Researchers successfully clone adult human stem cells

(Phys.org) —An international team of researchers, led by Robert Lanza, of Advanced Cell Technology, has announced that they have performed the first successful cloning of adult human skin cells into stem ...

Airbnb rental site raises $450 mn

Online lodging listings website Airbnb inked a $450 million funding deal with investors led by TPG, a source close to the matter said Friday.

Health care site flagged in Heartbleed review

People with accounts on the enrollment website for President Barack Obama's signature health care law are being told to change their passwords following an administration-wide review of the government's vulnerability to the ...